Capital Performance Advisors LLP Makes New Investment in Eli Lilly and Company (NYSE:LLY)

Capital Performance Advisors LLP purchased a new position in shares of Eli Lilly and Company (NYSE:LLY) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 373 shares of the company’s stock, valued at approximately $217,000.

Other large investors also recently bought and sold shares of the company. Vanguard Group Inc. raised its stake in shares of Eli Lilly and Company by 0.9% in the 3rd quarter. Vanguard Group Inc. now owns 70,575,602 shares of the company’s stock valued at $37,908,273,000 after acquiring an additional 659,838 shares during the period. Morgan Stanley raised its stake in shares of Eli Lilly and Company by 0.7% in the 3rd quarter. Morgan Stanley now owns 12,545,572 shares of the company’s stock valued at $6,738,605,000 after acquiring an additional 83,915 shares during the period. Northern Trust Corp raised its stake in shares of Eli Lilly and Company by 3.6% in the 3rd quarter. Northern Trust Corp now owns 10,158,275 shares of the company’s stock valued at $5,456,314,000 after acquiring an additional 355,317 shares during the period. International Assets Investment Management LLC raised its stake in shares of Eli Lilly and Company by 61,268.8% during the fourth quarter. International Assets Investment Management LLC now owns 7,342,780 shares of the company’s stock valued at $42,802,530,000 after purchasing an additional 7,330,815 shares during the period. Finally, Fisher Asset Management LLC lifted its position in shares of Eli Lilly and Company by 2.0% during the fourth quarter. Fisher Asset Management LLC now owns 4,544,585 shares of the company’s stock worth $2,649,130,000 after purchasing an additional 87,511 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on LLY shares. Barclays lifted their price target on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 7th. DZ Bank cut Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price target on the stock. in a research note on Wednesday, February 21st. Citigroup raised their price objective on Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a research note on Tuesday, April 2nd. The Goldman Sachs Group upped their target price on Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a research report on Thursday, April 11th. Finally, JPMorgan Chase & Co. raised their price target on shares of Eli Lilly and Company from $850.00 to $900.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 1st. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $757.95.

Eli Lilly and Company Stock Performance

LLY stock traded up $31.77 on Monday, reaching $766.74. The company’s stock had a trading volume of 3,396,224 shares, compared to its average volume of 3,090,840. Eli Lilly and Company has a 52 week low of $419.80 and a 52 week high of $800.78. The company has a market capitalization of $728.72 billion, a P/E ratio of 112.92, a price-to-earnings-growth ratio of 1.45 and a beta of 0.37. The firm has a fifty day moving average of $760.96 and a two-hundred day moving average of $673.52. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 1.03.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Monday, May 6th. The company reported $2.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The business had revenue of $8.77 billion during the quarter, compared to analyst estimates of $8.94 billion. During the same period in the prior year, the company posted $1.62 EPS. The business’s revenue for the quarter was up 26.0% compared to the same quarter last year. As a group, analysts predict that Eli Lilly and Company will post 13.82 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, June 10th. Investors of record on Thursday, May 16th will be issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 0.68%. Eli Lilly and Company’s dividend payout ratio (DPR) is 76.58%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.